Biochem/physiol Actions
Reversible: yes
General description
A cell-permeable macrocyle cyclotriazadisulfonamide derivative compound that inhibits HIV replication (IC50 = 300 nM to 3.3 µM) and entry into cells by blocking co-translational translocation of nascent CD4 across endoplasmic reticulum membranes. Its action appears to be highly selective in reducing the expression of human CD4 and it does not affect the level of any other cell surface marker studied. Does not affect CD4 mRNA levels in cells. Shown to be effective against HIV-1 subtypes A to H, AE, and O and human herpesvirus 7 (HHV-7; IC50, 300 nM to 1.5 µM) in T-cell lines and PBMCs. Also reported to block X4 HIV-1 NL4.3 and R5 SIVmac251 laboratory strains infection in human T cells. Can act synergistically with cellulose acetate phthalate (CAP) and other anti-HIV drugs to inhibit HIV-1 and SIV infections.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Vermeire, K., et al. 2008. Curr. HIV Res.6, 246.Bell, T. W., et al. 2006. J. Med. Chem.49, 1291.Vermeire, K., et al. 2004. AIDS.18, 2115.Vermeire, K., et al. 2002. Virology.302, 342.
Packaging
Packaged under inert gas
10 mg in Glass bottle
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: